Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Julphar
Baxter
Dow
Medtronic
QuintilesIMS
Harvard Business School
Colorcon
McKesson
UBS

Generated: January 23, 2018

DrugPatentWatch Database Preview

DEFERASIROX - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for deferasirox and what is the scope of deferasirox freedom to operate?

Deferasirox
is the generic ingredient in four branded drugs marketed by Novartis Pharms Corp, Actavis Elizabeth, and Novartis, and is included in four NDAs. There are three patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Deferasirox has seventy-four patent family members in forty-six countries.

There are twenty drug master file entries for deferasirox. One supplier is listed for this compound.

US Patents and Regulatory Information for DEFERASIROX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-001 Jan 26, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-002 May 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-003 Jan 26, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-001 Nov 2, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-003 Nov 2, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DEFERASIROX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 ➤ Subscribe ➤ Subscribe
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-001 Nov 2, 2005 ➤ Subscribe ➤ Subscribe
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-003 Nov 2, 2005 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 ➤ Subscribe ➤ Subscribe
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-002 Nov 2, 2005 ➤ Subscribe ➤ Subscribe
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DEFERASIROX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,723,742 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DEFERASIROX

Supplementary Protection Certificates for DEFERASIROX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0049 France ➤ Subscribe PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
2007001 Lithuania ➤ Subscribe PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0914118/01 Switzerland ➤ Subscribe PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
2007001,C0914118 Lithuania ➤ Subscribe PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
C 035/2006 Ireland ➤ Subscribe SPC 035/2006: 20070528, EXPIRES: 20210827
0 Finland ➤ Subscribe
C/GB07/002 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0248 Netherlands ➤ Subscribe 300248, 20170624, EXPIRES: 20210827
2006 00035 Denmark ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
McKinsey
Fuji
Accenture
Fish and Richardson
Cantor Fitzgerald
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot